NHS England approves use of F/TAF as alternative PrEP
1 June 2023. Related: HIV prevention and transmission.
HIV prevention and transmission
Generic versions of injectable PrEP could enable access to CAB-LA in low-income countries
6 April 2023. Related: Antiretrovirals, HIV prevention and transmission.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021
1 February 2023. Related: HIV prevention and transmission.
Latest statistics on HIV in the UK: data for 2021
1 December 2022. Related: Special reports, HIV prevention and transmission.
Cabotegravir-LA submitted to EMA for use as PrEP in Europe
1 December 2022. Related: HIV prevention and transmission.
HIV seroconversions on PrEP in Australian study are linked to low adherence
1 September 2022. Related: HIV prevention and transmission.
PrEP for women and PrEP in the UK: new leaflets 2022
3 August 2022. Related: HIV prevention and transmission.
Fantastic voyage: tracking adherence sensors in PrEP meds
1 July 2022. Related: HIV prevention and transmission.
ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
1 June 2022. Related: Antiretrovirals, Treatment access, HIV prevention and transmission.
A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
2 May 2022. Related: HIV prevention and transmission.
Zimbabwe decriminalises HIV transmission
2 May 2022. Related: HIV prevention and transmission, Other news.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
HIV vaccine study using mRNA technology starts in the US
1 April 2022. Related: HIV prevention and transmission.
South Africa approves dapivirine vaginal ring for HIV prevention
1 April 2022. Related: HIV prevention and transmission.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
1 March 2022. Related: Conference reports, HIV prevention and transmission.
EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?
20 December 2021. Related: Conference reports, HIV prevention and transmission.
US FDA approves long-acting cabotegravir injections for PrEP: price set at $22,000 a year
20 December 2021. Related: HIV prevention and transmission.
56 Dean Street reports M184V common with recent low adherence to PrEP and seven transmissions with good adherence
20 December 2021. Related: HIV prevention and transmission.
EACS 2021: a call for collaborations and for both HIV and COVID-19
31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Gilead withdraws application for F/TAF as PrEP in the EU
31 October 2021. Related: HIV prevention and transmission.
Imbokodo trial results highlight challenge of developing an HIV vaccine and urgent need for access to proven prevention tools
17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
Moderna registers HIV vaccine study
17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.
IAS 2021: New demands for better transgender heath care: No data no more
1 August 2021. Related: Conference reports, HIV prevention and transmission.
Phase 1 HIV mosaic vaccine study launched at Oxford university
1 August 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
HIV bNAbs prevent intravenous exposure to SHIV in macaques as PrEP
1 June 2021. Related: HIV prevention and transmission.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
R4P virtual conference (2021)
24 February 2021. Related: Conference reports, HIV prevention and transmission.
VRC01 antibody only prevents minority of HIV infections: AMP study results
24 February 2021. Related: Conference reports, HIV prevention and transmission.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
U=U is supported by a single undetectable viral load in the context of good adherence
22 January 2021. Related: Conference reports, HIV prevention and transmission.
PHE report on HIV and STIs during COVID-19
22 January 2021. Related: HIV prevention and transmission.
Worryingly low HIV knowledge among health workers at London hospital: 80% unaware of U=U, 36% worried about their risk from patients
9 December 2020. Related: Conference reports, HIV prevention and transmission.
Innovation benefits of cabotegravir LA injections for HIV PrEP will enable a closer FDA review
9 December 2020. Related: HIV prevention and transmission.
Once-monthly oral pill as PrEP against HIV: islatravir study to start in 2021
9 December 2020. Related: HIV prevention and transmission.
HIV in the UK: diagnoses continued to fall during 2019 but 42% are still late
11 November 2020. Related: HIV prevention and transmission.
Two-monthly cabotegravir injections prevent HIV infection in African women: HPTN 084 study recommends early unblinding
11 November 2020. Related: HIV prevention and transmission.
FTC exposure higher in young transgender men than cisgender controls
14 October 2020. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough
14 October 2020. Related: Conference reports, Paediatric care, PK and drug interactions, HIV prevention and transmission.
BASHH 2020 PEP guidelines: online for comment
14 October 2020. Related: Guidelines, HIV prevention and transmission.
EMA supports use of dapivirine vaginal ring to prevent HIV in high-incidence countries
28 August 2020. Related: HIV prevention and transmission.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083
22 July 2020. Related: Conference reports, HIV prevention and transmission.
UK government cuts HIV PrEP budget in England by a third
22 July 2020. Related: HIV prevention and transmission.
Cabotegravir long-acting injections prevent HIV as PrEP
1 June 2020. Related: HIV prevention and transmission.
PrEP recommended by NHS England (at last)
17 April 2020. Related: HIV prevention and transmission.
Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
27 March 2020. Related: HIV prevention and transmission, COVID-19: transmission & prevention, COVID-19.
Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
12 March 2020. Related: Conference reports, HIV prevention and transmission.
No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP
24 February 2020. Related: Conference reports, HIV prevention and transmission.
HIV in the UK – 2019 reports and data
24 February 2020. Related: HIV prevention and transmission, On the web.
Large phase 3 HIV vaccine study in south Africa is stopped early due to lack of efficacy
21 February 2020. Related: HIV prevention and transmission, Vaccines and microbicides.
i-Base guide to HIV testing and sexual transmission (January 2020)
29 January 2020. Related: Supplements, HIV prevention and transmission.
UK Guide to PrEP – November 2019
13 December 2019. Related: Supplements, HIV prevention and transmission.
US government claims patent infringement by Gilead Sciences over use of F/TAF and FTC/TDF as PrEP
15 November 2019. Related: Treatment access, HIV prevention and transmission.
PrEP linked to lower HIV incidence in US, independent of TasP
18 October 2019. Related: Conference reports, HIV prevention and transmission.
US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex
18 October 2019. Related: HIV prevention and transmission.
WHO update PrEP guidelines to include event-based dosing
30 September 2019. Related: Guidelines, HIV prevention and transmission.
UK issue joint guidelines on HIV discrimination in tattoo and beauty salons
30 September 2019. Related: Guidelines, HIV prevention and transmission.
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
23 August 2019. Related: Conference reports, HIV prevention and transmission.
Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year
24 July 2019. Related: Conference reports, HIV prevention and transmission.
Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50
19 June 2019. Related: Treatment access, HIV prevention and transmission.
Activists challenge block to generic PrEP and current US price of TDF/FTC
19 June 2019. Related: Treatment access, HIV prevention and transmission.
Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study
20 May 2019. Related: Conference reports, HIV prevention and transmission.